Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387298907> ?p ?o ?g. }
- W4387298907 abstract "Multiple sclerosis risk has a well-established polygenic component, yet the genetic contribution to disease course and severity remains unclear and difficult to examine. Accurately measuring disease progression requires long-term study of clinical and radiological outcomes with sufficient follow-up duration to confidently confirm disability accrual and multiple sclerosis phenotypes. In this retrospective study, we explore genetic influences on long-term disease course and severity; in a unique cohort of clinically isolated syndrome patients with homogenous 30-year disease duration, deep clinical phenotyping and advanced MRI metrics. Sixty-one clinically isolated syndrome patients [41 female (67%): 20 male (33%)] underwent clinical and MRI assessment at baseline, 1-, 5-, 10-, 14-, 20- and 30-year follow-up (mean age ± standard deviation: 60.9 ± 6.5 years). After 30 years, 29 patients developed relapsing-remitting multiple sclerosis, 15 developed secondary progressive multiple sclerosis and 17 still had a clinically isolated syndrome. Twenty-seven genes were investigated for associations with clinical outcomes [including disease course and Expanded Disability Status Scale (EDSS)] and brain MRI (including white matter lesions, cortical lesions, and brain tissue volumes) at the 30-year follow-up. Genetic associations with changes in EDSS, relapses, white matter lesions and brain atrophy (third ventricular and medullary measurements) over 30 years were assessed using mixed-effects models. HLA-DRB1*1501-positive (n = 26) patients showed faster white matter lesion accrual [+1.96 lesions/year (0.64-3.29), P = 3.8 × 10-3], greater 30-year white matter lesion volumes [+11.60 ml, (5.49-18.29), P = 1.27 × 10-3] and higher annualized relapse rates [+0.06 relapses/year (0.005-0.11), P = 0.031] compared with HLA-DRB1*1501-negative patients (n = 35). PVRL2-positive patients (n = 41) had more cortical lesions (+0.83 [0.08-1.66], P = 0.042), faster EDSS worsening [+0.06 points/year (0.02-0.11), P = 0.010], greater 30-year EDSS [+1.72 (0.49-2.93), P = 0.013; multiple sclerosis cases: +2.60 (1.30-3.87), P = 2.02 × 10-3], and greater risk of secondary progressive multiple sclerosis [odds ratio (OR) = 12.25 (1.15-23.10), P = 0.031] than PVRL2-negative patients (n = 18). In contrast, IRX1-positive (n = 30) patients had preserved 30-year grey matter fraction [+0.76% (0.28-1.29), P = 8.4 × 10-3], lower risk of cortical lesions [OR = 0.22 (0.05-0.99), P = 0.049] and lower 30-year EDSS [-1.35 (-0.87,-3.44), P = 0.026; multiple sclerosis cases: -2.12 (-0.87, -3.44), P = 5.02 × 10-3] than IRX1-negative patients (n = 30). In multiple sclerosis cases, IRX1-positive patients also had slower EDSS worsening [-0.07 points/year (-0.01,-0.13), P = 0.015] and lower risk of secondary progressive multiple sclerosis [OR = 0.19 (0.04-0.92), P = 0.042]. These exploratory findings support diverse genetic influences on pathological mechanisms associated with multiple sclerosis disease course. HLA-DRB1*1501 influenced white matter inflammation and relapses, while IRX1 (protective) and PVRL2 (adverse) were associated with grey matter pathology (cortical lesions and atrophy), long-term disability worsening and the risk of developing secondary progressive multiple sclerosis." @default.
- W4387298907 created "2023-10-04" @default.
- W4387298907 creator A5008287329 @default.
- W4387298907 creator A5025079255 @default.
- W4387298907 creator A5033264402 @default.
- W4387298907 creator A5037442059 @default.
- W4387298907 creator A5044775116 @default.
- W4387298907 creator A5062792951 @default.
- W4387298907 creator A5064378373 @default.
- W4387298907 creator A5064851379 @default.
- W4387298907 creator A5067383775 @default.
- W4387298907 creator A5069134946 @default.
- W4387298907 creator A5069328602 @default.
- W4387298907 creator A5072792511 @default.
- W4387298907 creator A5074741988 @default.
- W4387298907 creator A5082436384 @default.
- W4387298907 creator A5091342689 @default.
- W4387298907 date "2023-01-01" @default.
- W4387298907 modified "2023-10-18" @default.
- W4387298907 title "Genetic influences on disease course and severity, 30 years after a clinically isolated syndrome" @default.
- W4387298907 cites W1480299156 @default.
- W4387298907 cites W1523316823 @default.
- W4387298907 cites W1845331371 @default.
- W4387298907 cites W1865845132 @default.
- W4387298907 cites W1982991176 @default.
- W4387298907 cites W1987053154 @default.
- W4387298907 cites W1995173049 @default.
- W4387298907 cites W1995459626 @default.
- W4387298907 cites W2015799439 @default.
- W4387298907 cites W2027647892 @default.
- W4387298907 cites W2034967645 @default.
- W4387298907 cites W2040547343 @default.
- W4387298907 cites W2054422278 @default.
- W4387298907 cites W2055705508 @default.
- W4387298907 cites W2059369279 @default.
- W4387298907 cites W2062354909 @default.
- W4387298907 cites W2072034983 @default.
- W4387298907 cites W2082458487 @default.
- W4387298907 cites W2083984052 @default.
- W4387298907 cites W2087589796 @default.
- W4387298907 cites W2095839641 @default.
- W4387298907 cites W2102891551 @default.
- W4387298907 cites W2103649136 @default.
- W4387298907 cites W2114880905 @default.
- W4387298907 cites W2117446594 @default.
- W4387298907 cites W2122545833 @default.
- W4387298907 cites W2135900660 @default.
- W4387298907 cites W2142577589 @default.
- W4387298907 cites W2164392039 @default.
- W4387298907 cites W2192541999 @default.
- W4387298907 cites W2264731258 @default.
- W4387298907 cites W2408123531 @default.
- W4387298907 cites W2489432788 @default.
- W4387298907 cites W2589287792 @default.
- W4387298907 cites W2610956482 @default.
- W4387298907 cites W2764194024 @default.
- W4387298907 cites W2802306540 @default.
- W4387298907 cites W2968762354 @default.
- W4387298907 cites W2969409153 @default.
- W4387298907 cites W2981477552 @default.
- W4387298907 cites W2986704242 @default.
- W4387298907 cites W3144250827 @default.
- W4387298907 cites W3152941054 @default.
- W4387298907 cites W3209864050 @default.
- W4387298907 cites W4205972999 @default.
- W4387298907 cites W4309366524 @default.
- W4387298907 cites W4310461864 @default.
- W4387298907 cites W4382394400 @default.
- W4387298907 doi "https://doi.org/10.1093/braincomms/fcad255" @default.
- W4387298907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37841069" @default.
- W4387298907 hasPublicationYear "2023" @default.
- W4387298907 type Work @default.
- W4387298907 citedByCount "0" @default.
- W4387298907 crossrefType "journal-article" @default.
- W4387298907 hasAuthorship W4387298907A5008287329 @default.
- W4387298907 hasAuthorship W4387298907A5025079255 @default.
- W4387298907 hasAuthorship W4387298907A5033264402 @default.
- W4387298907 hasAuthorship W4387298907A5037442059 @default.
- W4387298907 hasAuthorship W4387298907A5044775116 @default.
- W4387298907 hasAuthorship W4387298907A5062792951 @default.
- W4387298907 hasAuthorship W4387298907A5064378373 @default.
- W4387298907 hasAuthorship W4387298907A5064851379 @default.
- W4387298907 hasAuthorship W4387298907A5067383775 @default.
- W4387298907 hasAuthorship W4387298907A5069134946 @default.
- W4387298907 hasAuthorship W4387298907A5069328602 @default.
- W4387298907 hasAuthorship W4387298907A5072792511 @default.
- W4387298907 hasAuthorship W4387298907A5074741988 @default.
- W4387298907 hasAuthorship W4387298907A5082436384 @default.
- W4387298907 hasAuthorship W4387298907A5091342689 @default.
- W4387298907 hasBestOaLocation W43872989071 @default.
- W4387298907 hasConcept C126322002 @default.
- W4387298907 hasConcept C126838900 @default.
- W4387298907 hasConcept C142724271 @default.
- W4387298907 hasConcept C143409427 @default.
- W4387298907 hasConcept C143998085 @default.
- W4387298907 hasConcept C146638467 @default.
- W4387298907 hasConcept C187212893 @default.
- W4387298907 hasConcept C203014093 @default.
- W4387298907 hasConcept C2779134260 @default.
- W4387298907 hasConcept C2780640218 @default.